AMGN vs. VRTX, REGN, GILD, MRNA, SGEN, BIIB, ALNY, BMRN, NBIX, and INCY
Should you be buying Amgen stock or one of its competitors? The main competitors of Amgen include Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Gilead Sciences (GILD), Moderna (MRNA), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), and Incyte (INCY). These companies are all part of the "medical" sector.
Vertex Pharmaceuticals (NASDAQ:VRTX) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, community ranking, risk, analyst recommendations, institutional ownership, valuation and earnings.
Vertex Pharmaceuticals presently has a consensus target price of $438.62, indicating a potential downside of 9.20%. Amgen has a consensus target price of $305.65, indicating a potential upside of 0.21%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Amgen is more favorable than Vertex Pharmaceuticals.
In the previous week, Vertex Pharmaceuticals had 10 more articles in the media than Amgen. MarketBeat recorded 31 mentions for Vertex Pharmaceuticals and 21 mentions for Amgen. Vertex Pharmaceuticals' average media sentiment score of 1.03 beat Amgen's score of 0.83 indicating that Amgen is being referred to more favorably in the news media.
Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.
Vertex Pharmaceuticals has a net margin of 39.46% compared to Vertex Pharmaceuticals' net margin of 12.74%. Vertex Pharmaceuticals' return on equity of 156.21% beat Amgen's return on equity.
Vertex Pharmaceuticals has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.
91.0% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.2% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 0.7% of Amgen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Vertex Pharmaceuticals received 30 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 75.63% of users gave Vertex Pharmaceuticals an outperform vote while only 72.41% of users gave Amgen an outperform vote.
Summary
Vertex Pharmaceuticals and Amgen tied by winning 9 of the 18 factors compared between the two stocks.
Get Amgen News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
